# Recent Advances in Microfluidic Chip Technology for Laboratory Medicine: Innovations and Artificial Intelligence Integration

**Authors:** Hong Cai, Dongxia Wang, Yiqun Zhao, Chunhui Yang

PMC · DOI: 10.3390/bios16020104 · Biosensors · 2026-02-05

## TL;DR

Microfluidic chips are revolutionizing lab medicine by enabling fast, automated diagnostics with small samples, and combining them with AI improves their accuracy and usefulness.

## Contribution

This paper reviews recent innovations in microfluidic chip design, biosensor integration, and AI-driven advancements for clinical applications.

## Key findings

- Microfluidic chips with advanced biosensors enable real-time detection of biomarkers like tumor cells and exosomes.
- AI integration enhances automation and analytical capabilities, leading to smarter diagnostic platforms.
- Emerging applications include neuroscience diagnostics and microbiome profiling, showing broad clinical potential.

## Abstract

Microfluidic chip technologies, also known as lab-on-a-chip systems, have profoundly transformed laboratory medicine by enabling the miniaturization, automation, and rapid processing of complex diagnostic assays using minimal sample volumes. Recent advances in chip design, fabrication methods—including 3D printing, modular and flexible substrates—and biosensor integration have significantly enhanced the performance, sensitivity, and clinical applicability of these devices. Integration of advanced biosensors allows for real-time detection of circulating tumor cells, nucleic acids, and exosomes, supporting innovative applications in cancer diagnostics, infectious disease detection, point-of-care testing (POCT), personalized medicine, and therapeutic monitoring. Notably, the convergence of microfluidics with artificial intelligence (AI) and machine learning has amplified device automation, reliability, and analytical power, resulting in “smart” diagnostic platforms capable of self-optimization, automated analysis, and clinical decision support. Emerging applications in fields such as neuroscience diagnostics and microbiome profiling further highlight the broad potential of microfluidic technology. Here, we present findings from a comprehensive review of recent innovations in microfluidic chip design and fabrication, advances in biosensor and AI integration, and their clinical applications in laboratory medicine. We also discuss current challenges in manufacturing, clinical validation, and system integration, as well as future directions for translating next-generation microfluidic technologies into routine clinical and public health practice.

## Linked entities

- **Diseases:** cancer (MONDO:0004992), infectious disease (MONDO:0005550)

## Full-text entities

- **Genes:** MB (myoglobin) [NCBI Gene 4151] {aka MYOSB, PVALB}, TNNI3 (troponin I3, cardiac type) [NCBI Gene 7137] {aka CMD1FF, CMD2A, CMH7, RCM1, TNNC1, cTnI}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}
- **Diseases:** fatigue (MESH:D005221), stroke (MESH:D020521), AI (MESH:C538142), arrhythmias (MESH:D001145), dengue (MESH:D003715), bleeding (MESH:D006470), non-small cell lung cancer (MESH:D002289), neurological disorders (MESH:D009461), metabolic disorders (MESH:D008659), fever illnesses (MESH:D005334), influenza (MESH:D007251), injury to (MESH:D014947), lung infection (MESH:D012141), inflammatory (MESH:D007249), melanoma (MESH:D008545), preeclampsia (MESH:D011225), Alzheimer's (MESH:D000544), Down syndrome (MESH:D004314), diabetes (MESH:D003920), Cancer (MESH:D009369), ovarian cancer (MESH:D010051), bacterial infections (MESH:D001424), heart failure (MESH:D006333), breast cancer (MESH:D001943), Sepsis (MESH:D018805), Infectious Disease (MESH:D003141), malaria (MESH:D008288), Zika (MESH:D000071243), neutropenia (MESH:D009503), prostate and colorectal cancers (MESH:D015179), leukemia (MESH:D007938), epileptics (MESH:D004827), thrombosis (MESH:D013927), dehydration (MESH:D003681), toxicity (MESH:D064420), acute myocardial infarction (MESH:D009203), cardiovascular diseases (MESH:D002318), infections (MESH:D007239), COVID (MESH:D000086382)
- **Chemicals:** vancomycin (MESH:D014640), PMMA (MESH:D019904), progesterone (MESH:D011374), gold (MESH:D006046), carbon (MESH:D002244), polymer (MESH:D011108), lactate (MESH:D019344), agarose (MESH:D012685), PDMS (MESH:C013830), creatinine (MESH:D003404), glucose (MESH:D005947), tacrolimus (MESH:D016559), silicon (MESH:D012825), COC (-), polyester (MESH:D011091), carbon nanotube (MESH:D037742)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Human immunodeficiency virus 1 (no rank) [taxon 11676], Escherichia coli (E. coli, species) [taxon 562], Mycoplasmoides pneumoniae (Filterable agent of primary atypical pneumonia, species) [taxon 2104], Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938137/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938137/full.md

## References

144 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938137/full.md

---
Source: https://tomesphere.com/paper/PMC12938137